NVP-DPP728 dihydrochloride_product_DataBase

Bioactivity	NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus[1][2].
Target	Ki: 11 nM (DPP-IV)
Invitro	NVPDPP728 inhibits human and rat plasma DPP-IV (IC50s: 5-10 nM) with >15 000-fold selectivity relative to DPP-II and a range of proline-cleaving proteases[1].
In Vivo	NVP-DPP728 (3.72 mg/kg; p.o.) inhibits DPP-IV and improves insulin secretion and glucose tolerance, probably through augmentation of the effects of endogenous GLP-1[2]. Animal Model:
Name	NVP-DPP728 dihydrochloride
CAS	207556-62-5
Formula	C15H20Cl2N6O
Molar Mass	371.26
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. T E Hughes, et al. NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry. 1999 Sep 7;38(36):11597-603. [2]. B Balkan, et al. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia. 1999 Nov;42(11):1324-31.

PeptideDB